☆ 4.8 Letter

Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

GASTROENTEROLOGY (2021)

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

Michael D. Kappelman et al.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Kathryn E. Stephenson et al.

Summary: The study evaluated the immunogenicity of the Ad26.COV2.S vaccine in human participants, showing rapid induction of spike-specific humoral and cellular immune responses. Various antibody subclasses, Fc receptor binding properties, and antiviral functions were induced, along with CD4+ and CD8+ T-cell responses.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

Serre-Yu Wong et al.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy et al.

Summary: Infliximab treatment in patients with inflammatory bowel disease results in attenuated serological responses to a single dose of the SARS-CoV-2 vaccine. Delayed second dosing should be avoided in these patients, as vaccination after SARS-CoV-2 infection or a second dose leads to seroconversion in most individuals.

GUT (2021)

添加到收藏夹

Letter Medicine, General & Internal

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

William A. Werbel et al.

ANNALS OF INTERNAL MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Nassim Kamar et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

相关参考文献

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

导出引文

分享论文